Report to Donors 2023

We will **Beat Childhood Cancer** by funding research and clinical trials for children with solid tumor cancers creating options for kids **TODAY** to increase survival and decrease toxicity.

Our Vision

Change the story for the next family to help every child, everywhere survive and thrive.

BEAT CHILDHOOD CANCER

For Every Child, EVERYWHERE

2023 Financials

Where The Money Goes



Where The Money Comes From



A letter from Sarah Bartosz, Executive Director

The Beat Childhood Cancer Foundation is built on a singular commitment – a commitment to every child and every family with five words: ***we will beat childhood cancer.***

2023 realized a remarkable triumph for the organization when DFMO (now IWILFIN) became FDA approved as maintenance therapy for high-risk neuroblastoma patients. This groundbreaking advancement in treatment aimed to prevent relapse was achieved thanks to the passion of patients and families and the generosity of our partners.

What we have learned over the last decade is that by funding a program designed to advance therapies for each patient uniquely using personalized medicine, the Beat Childhood Cancer Research Consortium is uncovering clues, medicines, and cures connecting the dots to solutions for every child, everywhere across all solid tumor cancers.

We know what success looks like and we are now aiming higher and reaching further to ***fund, find, and fuel*** the therapies that will ensure children diagnosed with cancer survive and thrive. We are just getting started. We will beat childhood cancer . . . will you join us?

With golden hope,

Sarah

Where The Money Goes represents overall spending during the 2023 Fiscal Year. ***Where The Money Comes From*** represents **$1,809,266,** the total funds received by the organization during the 2023 Fiscal Year.

“I WILL do all I can to protect every child, everywhere from relapse.”

DFMO IS NOW IWILFIN®

IWILFIN IS NOW FDA APPROVED!

IWILFIN is the first and only oral maintenance therapy that may help reduce the risk of relapse for children with high-risk neuroblastoma.

52% reduced risk of relapse

In clinical trial, patients who received IWILFIN had a 52% reduced risk of relapse

68% reduced risk of death

In clinical trial, patients who received IWILFIN had a 68% reduced risk of death

- **Cuts the risk of relapse in half**
- **Convenient to use**
- **Well tolerated with manageable side effects**

The inspiration behind IWILFIN

The name IWILFIN was inspired by 2 high-risk neuroblastoma survivors, Will and Finn. Their bravery and treatment outcomes helped pave the way for wider development of this breakthrough maintenance therapy.

About Will

Will was diagnosed with high-risk neuroblastoma as an infant. He underwent a 7- year treatment journey, which included being a participant in the first phase 1 investigational trial conducted for IWILFIN. Will is now an adult, and the results of his participation in that first trial paved the way for the continued development of IWILFIN.

About Finn

Finn was diagnosed with Stage 4, MYCN - amplified high-risk neuroblastoma at 3 months old. After a long and difficult upfront treatment journey, Finn achieved remission and went on to receive IWILFIN as maintenance therapy for 2 years. Finn received his final dose of IWILFIN in 2022, just in time for his promotion to big brother.

Learn more at IWILFIN.com

"Beat Childhood Cancer brings hope for EVERY CHILD." - Dr. Giselle Sholler

OUR TEAM

Sarah Bartosz
Executive Director
sarah@beatcc.org

Savannah Billett
Associate
Development Director
savannah@beatcc.org

Yvette Pullara
Operations Director
yvette@beatcc.org

Patrick Lacey
Founder and
Executive Advisor to
the BeatCC Research
Consortium
pat@beatcc.org

Find Us:
BeatCC.org
@beatchildhoodcancer

BEAT CHILDHOOD CANCER